Results 1 to 10 of about 327 (130)
Effect of Thrombopoietin Receptor Agonist on Pregnant Mice [PDF]
Pharmaceutics, 2022 Thrombopoietin receptor agonists (TPO-RAs) are an effective treatment for refractory immune thrombocytopenia (ITP). However, the use of TPO-RAs is limited for ITP in pregnant women due to concerns about fetal toxicity.
Kensaku Nakai +9 more
doaj +5 more sources
Therapeutic Advances in Hematology, 2022 This report describes the first case of splenic injury in a patient with p.V1316M-associated von Willebrand disease type 2B (VWD2B) with chronic thrombocytopenia, successfully treated with nonoperative management including von Willebrand factor (VWF ...
Caterina Casari +8 more
doaj +2 more sources
Metabolites, 2022 The thrombopoietin receptor agonist romiplostim (RP) was recently approved by the US Food and Drug Administration for improving survival in patients acutely exposed to myelosuppressive doses of radiation. Our previous studies with mice have shown that RP
Yoshiaki Sato +2 more
doaj +3 more sources
Folia Medica Indonesiana, 2016 Idiopathic thrombocytopenic purpura is a autoimmune disease characterized thrombocytopenia casued by excessive platelet destruction. However, both platelet destruction and reduced thrombopoietin level are occurred in some cases. Therefore, new management
Jefri Pratama Susanto
doaj +3 more sources
Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia [PDF]
Therapeutic Advances in Hematology, 2019 The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors commonly used to treat immune thrombocytopenia (ITP). There are three agents that have been investigated for the treatment of chronic ITP: the peptide agent romiplostim and the small molecule agents eltrombopag and avatrombopag.
Hanny Al-Samkari, David Kuter
exaly +4 more sources
Platelets, 2017 We present here a 63-year old woman with a long history of immune thrombocytopenia. She was hospitalized for a traumatic intracranial hemorrhage with thrombocytopenia.
O. Espitia +5 more
doaj +2 more sources
Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia
Research Results in Pharmacology, 2023 Introduction: Thrombopoietin receptor agonists are commonly second-line drugs in immune thrombocytopenia (ITP) pharmacotherapy in children and prescribed for chronic ITP refractory to first-line therapy.
Olga S. Levchenkova +4 more
doaj +1 more source
Peptide agonists of the thrombopoietin receptor [PDF]
Stem Cells, 1998 We have screened a variety of L-amino acid peptide libraries against the extracellular domain of the human thrombopoietin (HuTPO) receptor, c-Mpl. A large number of peptide ligands were recovered and categorized into two families. Peptides from each family compete with the binding of HuTPO and with the binding of peptides from the other familiy ...
W J, Dower +5 more
openaire +2 more sources
Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia [PDF]
International Journal of Molecular Sciences, 2021 In the last decade, improvements in genetic testing have revolutionized the molecular diagnosis of inherited thrombocytopenias (ITs), increasing the spectrum of knowledge of these rare, complex and heterogeneous disorders. In contrast, the therapeutic management of ITs has not evolved in the same way.
José María Bastida +3 more
openaire +2 more sources
Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia
BMC Cancer, 2023 Background Thrombocytopenia is a common complication in cancer patients undergoing chemotherapy. Chemotherapy-induced thrombocytopenia (CIT) leads to dose reduction and treatment delays, lowering chemotherapy efficacy and survival rate.
Jiwon Shin +7 more
doaj +1 more source